Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Directorate Change

22 Sep 2025 07:00

RNS Number : 2184A
Belluscura PLC
22 September 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

22 September 2025

 

 

Belluscura plc

("Belluscura" or the "Company")

 

 

Update regarding Proposed Funding

Board changes

 

 

Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that, further to the statement issued on 12 September 2025, discussions with Omaha Value, Inc. and a connected company called AI Ventures, Inc, regarding the proposed fundraising, have not yet been concluded as anticipated. Discussions have continued, however, with Omaha Value, Inc, AI Ventures, Inc and other potential investors with a view to the refinancing of Belluscura and Belluscura LLC, the Company's main trading subsidiary.

 

As a result, Belluscura LLC has taken steps to enable it to meet its immediate cash requirements.  Whilst the senior management team and those employees responsible for Sales and Shipping have been retained, to ensure the continued fulfilment of customer orders, the employment contracts of 15 of Belluscura LLC's 25 employees in the United States have been terminated.

 

Board changes

 

The Company also announces that Bob Rauker remains CEO of Belluscura LLC but has resigned from the board of Belluscura with immediate effect.

 

Ric Piper, who has been a Director of Belluscura since its AIM flotation in 2021, has also resigned as a non-executive director of Belluscura with immediate effect.

 

 

The ongoing funding discussions mean that the Company is still not yet able to finalise the 2024 Annual Report and Accounts and as a result trading in the Company's shares on AIM remains suspended.

 

 

A further announcement will be made in due course.

 

 

For further information please contact:

 

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Paul Tuson, Chairman

 

SPARK Advisory Partners Limited - Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Dillon Wall

Dowgate Capital Limited - Joint Broker

Tel: +44 (0)20 3903 7715

Russell Cook / Daniel Ingram

Allenby Capital Limited - Joint Broker

Tel: +44 (0)20 3328 5656

Guy McDougall / Amrit Nahal (Sales and Corporate Broking)

Jeremy Porter / Lauren Wright (Corporate Finance)

MHP - Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

Katie Hunt / Matthew Taylor

email: Belluscura@mhpgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPKDBDBBKBFCB
Date   Source Headline
12th Oct 202312:42 pmBUSForm 8.3 - Belluscura plc
12th Oct 20239:55 amRNSForm 8.3 - BELLUSCURA PLC
11th Oct 20234:20 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20235:10 pmRNSForm 8.3 - TMT ACQUISITION PLC
10th Oct 20235:09 pmRNSForm 8.3 - [BELLUSCURA PLC]
10th Oct 20234:40 pmRNSForm 8.3 - Belluscura PLC
10th Oct 20234:21 pmRNSForm 8.3 - BELLUSCURA PLC
10th Oct 20234:19 pmRNSForm 8.3 - TMT Acquisition PLC
10th Oct 20233:54 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:52 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:47 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:45 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:42 pmRNSForm 8.3 - Belluscura plc
10th Oct 20233:28 pmGNWForm 8.3 - Belluscura PLC
9th Oct 20236:11 pmRNSForm 8.3 - Belluscura Plc
9th Oct 20232:32 pmRNSForm 8.3 - Belluscura PLC
9th Oct 20231:39 pmRNSRule 2.9 Announcement
9th Oct 20238:10 amRNSRule 2.9 Announcement
6th Oct 202312:48 pmRNSConditional Allotment and Issue of Placing
5th Oct 20234:49 pmRNSForm 8.3 - Belluscura PLC
3rd Oct 20236:28 pmRNSReplacement - Placing of Unsecured CLNs
3rd Oct 20231:53 pmRNSDirectorate Change
3rd Oct 20231:38 pmRNSPlacing of Unsecured Convertible Loan Notes
3rd Oct 20231:30 pmRNSStatement re Possible Offer
3rd Oct 20231:30 pmRNSStatement regarding possible offer
26th Sep 20237:00 amRNSBelluscura Receives Approval in Hong Kong
14th Sep 20234:26 pmRNSResult of AGM
13th Sep 20237:00 amRNSHalf-year Report
30th Aug 20237:00 amRNSBelluscura Enters Exclusive License Agreement
16th Aug 20237:00 amRNSOrders for over 6,500 DISCOV-R™ received
1st Aug 20237:00 amRNSBelluscura Signs Distribution Agreement
12th Jul 20237:00 amRNSNotice of AGM and Annual Report 2022
29th Jun 20237:00 amRNSBelluscura Commences Premarket Launch of DISCOV-R™
29th Jun 20237:00 amRNSFinal Results for the year ended 31 December 2022
15th Jun 20237:00 amRNSShare allotment; Director/PDMR Shareholding; Appt.
14th Jun 202312:28 pmRNSResult of General Meeting
1st Jun 20237:00 amRNSResult of Retail Offer
26th May 20237:00 amRNSProposed Board Appointment
25th May 202311:15 amRNSRetail Offer to raise up to £0.5m
25th May 202311:00 amRNSProposed Placing and Subscriptions to raise £3.0m
28th Apr 20237:00 amRNSAdditional Broker Option - Extension
20th Apr 20238:19 amRNSExercise of Warrants and Total Voting Rights
3rd Apr 20237:00 amRNSBelluscura begins manufacturing in China
30th Mar 20237:00 amRNSChange of Auditor
24th Feb 20237:00 amRNSBelluscura POC now marketed through GoodRx®
16th Feb 202311:59 amRNSResult of General Meeting
10th Feb 20237:00 amRNSResult of Broker Option
31st Jan 20233:41 pmRNSPosting of Circular
27th Jan 20232:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.